All News
LDCT to assess disease progression in early axSpA:
-Data from SPACE cohort 67 pts (>50% male,>80% hLAB27+)
- LDCT at baseline and 2 years apart.
-Overall 22% pt with net disease progression.
-Spine progression most frequent on thoracic spine.
-Good reliability in assessing https://t.co/M2jkDusD41
Links:
Adela Castro AdelaCastro222 ( View Tweet)
🎯 Early MTX hits the mark — but only in ACPA-negative.
In TREAT EARLIER, 1 year of MTX led to lasting benefits at 5 years:
➖ Less RA
➖ Better function
❌ No benefit in ACPA+
Abstract#OP0324 @RheumNow #EULAR2025
Jiha Lee JihaRheum ( View Tweet)
#ANCA #vasculitis is not created equally
REVEAL cohort 588 ANCA
Initial & 12 months #BVAS (activity index)
mean ⬇️BVAS over 1 yr in all groups
#GPA #MPA #eGPA
5yr survival not = over time
⬆️survival in eGPA & GPA vs MPA
#POS0329 #EULAR2025 @RheumNow @eular_org https://t.co/cUKytqNZnS
Links:
Janet Pope Janetbirdope ( View Tweet)
#EULAR2025 Abstr#POS0325 Immunosuppressant-free is not only confined to CAR-T. Our cohort study in #SLE: 20% patients were “Super-Responder” (>3yrs response) inc. 7% IS-free after one Rituximab cycle. Non-European, APS & shorter disease duration predicted super-response @RheumNow https://t.co/nPIYpGoynR
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
So we used to get taught about bimodal age distribution of RA onset - young people and old people.
Actually, it’s early middle age where RA diagnoses have now grown globally over 30y - right in peak productivity
Global Burden of Disease data
#EULAR2025 OP0240-HPR @RheumNow https://t.co/8yyrex00yy
David Liew drdavidliew ( View Tweet)
Intraarticular IL-1Ra Gene Therapy in Knee Osteoarthritis
In a dose-escalation trial in nine participants, they observed that a single intra-articular injection of the gene product led to an increase in IL-1Ra in the synovial fluid that remained elevated for up to a year. There https://t.co/qi0qHPd06j
Dr. John Cush RheumNow ( View Tweet)
In #axSpA post #TNFi-IR
What to use next?
👇
#ATTRA registry
90% #SpA on #bDMARDs are captured
Comparison of
TNFi to ▶️
2nd TNFi vs
#IL17i
▶️No diff in #retention
✅better #BASDAI and other outcomes w TNFi!
❎less safety
🤔
#EULAR2025 @RheumNow @eular_org
Abst#POS0116 https://t.co/7mqFfD4Amf
Janet Pope Janetbirdope ( View Tweet)
Rheumatology #AI to optimize rheumatology triage. Only 53 percent correlation between the AIs diagnosis with rheumatologists final diagnosis. Not sure if we want 47 percent pts to drop off...without a chance for diagnosis?
#POS0883 #EULAR2025 @RheumNow https://t.co/UWsCHG00t1
Bella Mehta bella_mehta ( View Tweet)
Multimodal data using clinical histological and serological predictors in renal function in #sle nephritis. Using the AMP SLE data.
Low baseline eGFR and histological damage predicted worsening renal function but not NIH activity index
#POS0173 #EULAR2025 @RheumNow @andreafa https://t.co/Eh8dZXHRVX
Links:
Bella Mehta bella_mehta ( View Tweet)
?fishing for + results #EULAR2025
⚠️opinion
be aware that results do not live or die on P values
Impt findings beyond primary endpoints may be Impt beyond P<0.05
Conversely
Unexpected P values in a database
❎interpret w caution
Consider as hypothesis only
@RheumNow
Janet Pope Janetbirdope ( View Tweet)
Software enhances treat to target outcomes for #RA GoTreatIT
P0S0750 ##EULAR2025 @RheumNow https://t.co/GpihWr5KLA
Links:
Bella Mehta bella_mehta ( View Tweet)
Does having a synovitis in a specific joint predicts Rx damage in that same joint?
Yes
Can US synovitis predict Rx progression better than clinical synovitis at the joint level?
Not really
At 1 year, only US synovitis is, both B-mode and Doppler ass w/ Rx prog, in particular https://t.co/Wu6dDqIUYn
Aurelie Najm AurelieRheumo ( View Tweet)
OP0176: Among D2T PsA pts, 43% lacked inflammation on imaging—despite symptoms.
Clinical + US split them into PIPsA vs NIPsA, helping distinguish who needs escalation vs who doesn’t.
A step toward smarter care in D2T PsA.
@RheumNow #EULAR2025 https://t.co/E9igwvDPPN
Jiha Lee JihaRheum ( View Tweet)
PHOENYCS GO🏃: Dapirolizumab pegol (DZP) led to higher rates of LLDAS (41% vs 20%) & DORIS remission (19% vs 8%) at wk48 vs PBO+SOC. DZP showed earlier & more sustained disease control, advancing T2T in SLE.
@RheumNow #EULAR2025 #OP0201 https://t.co/zuxBELxTDd
Mrinalini Dey DrMiniDey ( View Tweet)
FAPI-PET/CT - detecting synovial and enthesial fibroblast activation- predicts the development of #psoriatic_arthritis in patients with psoriasis and arthralgia
✨️ A promising tool for early diagnosis of PsA
Giulia Corte et al.
OP#0174
#EULAR2025
@RheumNow https://t.co/QVmoECIhBI
Nelly ZIADE 🍀 Nellziade ( View Tweet)
✨️ New Definition Alert
The GRAPPA definition of
C2M (Complex to Manage)
&
D2T (Difficult to Treat)
#Psoriatic_arthritis
A hope for having a homogeneous and widely accepted definition for future clinical research
Presented at #EULAR2025
Proft et al.
OP#0175
@RheumNow https://t.co/et9cuMROkb
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Premature death in RA still exists, and varies according to race/ethnicity demographic groups
Nationwide US CDC's MCoD database analysis
-Mortality rates
11x higher American Indians
3x higher Black or African American people
-Median age at death with RA
9-10 years younger https://t.co/FTRWPk7Wz0
Aurelie Najm AurelieRheumo ( View Tweet)
RA-related premature mortality highest in American Indians--> 3.6x odds of death in <65 vs White peers, w/ no improvement over 22 yrs. COVID widened the gap. Need to address structural & social drivers of early death in RA, & wider health disparities.
@RheumNow #EULAR2025 #OP0197
Mrinalini Dey DrMiniDey ( View Tweet)
Yes, it is relevant to ask patients about physical joint strain in RA and propose strain specific interventions
In ACPA+ RA pts for each 10% increase in strain, 7% increase in SJC44 and 5% MRI inflammation
POS0166 #EULAR2025 @RheumNow https://t.co/jwpi7S8JTW
Aurelie Najm AurelieRheumo ( View Tweet)
We should address patients anxiety at RA diagnosis:
cohort 250+ newly diagnosed RA pts
-49% reported anxiety
-41% by 3 months
Anxiety asso w/ CDAI, PROs and 3-5 fold increase in prescription of bio/tsDMARDs
Analysis reasonably adjusted
POS0163 #EULAR2025 @RheumNow https://t.co/2gejEkRQhO
Aurelie Najm AurelieRheumo ( View Tweet)
